Thursday, February 2, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

New BARDA Initiative to Develop Universal Flu Vaccine

by Global Biodefense Staff
February 2, 2015
Pandemic Influenza Research & Countermeasures

The Department of Health and Human Services (HHS), through the Biomedical Advanced Research and Development Authority (BARDA) is launching a new initiative supporting the advanced development of influenza vaccine candidates with the goal to provide enhanced, long-lasting protection from a broad range of influenza viruses within and across subtypes.

These new vaccines will be more effective than current vaccines in providing protection from influenza infection in people of all ages and in people generally considered high-risk for severe disease associated with influenza infection.

Additionally, these new vaccines may serve as a priming dose during non-pandemic periods to enable a single dose of a pandemic influenza vaccine to be effective. As such, promising experimental data providing evidence that the new vaccine may serve as a primer for a pandemic influenza vaccine booster will be evaluated favorably.

Seasonal influenza vaccines, which are produced and administered annually, are only 30% to 70% effective. Excess morbidity and mortality caused by seasonal influenza virus disease can be devastating in terms of years of life lost and economic productivity. The emergence of novel strains of influenza viruses also present a public health threat, with potential rapid global spread among people with no pre-existing immunity to the virus, causing catastrophic morbidity and mortality.

To support these efforts, BARDA intends to publish a Request for Proposal (RFP) to develop, manufacture, and evaluate more effective influenza vaccine candidates toward US licensure. The anticipated period of performance includes a four to five year base period with a four to five year option period.

The RFP is anticipated to be released on or about February 11, 2015, with proposals being due April 11, 2015. Multiple awards may result from this solicitation with an estimated award date of September 2015.

Further details are available via Solicitation Number: BARDA_Universal_Influenza_Synopsis.

Tags: ASPRBARDAEmerging ThreatsHHSInfluenzaPandemicUniversal Flu VaccineVaccines

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions
Pathogens

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks
Pathogens

NIH Grant Awarded to Study Evolution of Lyme Disease Bacteria in Deer Ticks

December 7, 2022
Bat Virus Receptor Studies Vital to Predict Spillover Risk
Pathogens

Bat Virus Receptor Studies Vital to Predict Spillover Risk

December 7, 2022
Load More

Latest News

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023
Biodefense Headlines – 17 January 2023

Biodefense Headlines – 17 January 2023

January 17, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC